Objective: We tested the hypothesis that transendothelial exchange of low-density lipoprotein (LDL) is influenced by the presence of severe atherosclerosis; we previously found this exchange elevated in diabetes patients. Methods: By an in vivo isotope method, we compared transendothelial LDL exchange in 24 patients with angiographically verified coronary atherosclerosis, 11 patients with angiographically verified peripheral atherosclerosis, 60 patients with diabetes, and in 42 controls. Autologous 131-iodinated LDL ( 131 I-LDL) and 125-iodinated albumin ( 125 I-albumin) were injected intravenously (i.v.), and the 1-h fractional escape rates (FER LDL and FER alb ) were taken as indices of transendothelial exchange. Results: Patients with coronary or peripheral atherosclerosis had FER LDL similar to that of controls [4.3 (3.5-5.1) and 3.2 (2.3-4.1) versus 4.2 (3.7-4.7)%/h; PN0.05], even after adjustment for LDL distribution volume (DV LDL ). In contrast, diabetes patients had significantly higher FER LDL than controls [5.2 (4.6-5.7) versus 4.2 (3.7-4.7)%/h; Pb0.05]. This difference was even more pronounced after correction for the distribution volume of LDL. Compared with controls, FER alb was not elevated in patients with coronary atherosclerosis, possibly elevated in patients with peripheral atherosclerosis, but was elevated in diabetes patients. There was a tight positive correlation between FER LDL and FER alb in all groups of patients and controls. Conclusion: Transendothelial exchange of low-density lipoprotein is not elevated in patients having severe atherosclerosis. This suggests that the observed vascular leakiness in diabetes precedes and possibly contributes to accelerated atherosclerosis in diabetes.
Introduction
Although hyperlipidemia is a well-established cause of atherosclerosis, its prognostic specificity and sensitivity for the development of cardiovascular disease are far from 100% [1] . We therefore hypothesized that transendothelial exchange of lipoproteins from blood to the vessel wall, in addition to lipoprotein levels in plasma, determines the degree of atherosclerosis [2] . According to this, the atherogenic effect of lipoproteins may be augmented if transendothelial exchange is high, and vice versa if transendothelial exchange is low.
We have developed a noninvasive in vivo isotope technique for estimating transendothelial exchange of lowdensity lipoprotein (LDL) in humans: we measure fractional escape rate of LDL from the intravascular compartment during 1-h after intravenous (i.v.) injection of radiolabeled autologous LDL (fractional escape rate of LDL, FER LDL ) [3] . Using this method, we previously found that type 1 and type 2 diabetic patients have higher FER LDL than healthy controls [3, 4] , suggesting that the accelerated development of atherosclerosis in diabetes could partly be due to the increased vascular leakiness of lipoproteins that precedes atherosclerosis. This is analogous with previous observations of increased fractional escape rate of albumin (FER alb ) in patients with diabetes mellitus versus controls [5, 6] . However, atherosclerosis with its many endothelial lesions could in itself be the cause of increased FER LDL , rather than increased FER LDL leading to atherosclerosis: arterial lesions increase arterial LDL influx [7] . In accordance with this hypothesis, we have previously observed increased FER alb in patients with severe atherosclerosis versus controls [2] . It is, however, unknown whether FER LDL is also higher in atherosclerotic patients compared with healthy individuals.
In the present study, we tested the hypothesis that transendothelial exchange of low-density lipoprotein is influenced by the presence of severe atherosclerosis: we compared FER LDL and FER alb in patients with severe coronary or peripheral atherosclerosis with values in diabetic patients as well as in healthy controls. We also measured LDL diameter and distribution volumes of both LDL and albumin (DV LDL and DV alb ), as this could affect FER values.
Methods

Subjects
We studied four groups of subjects with similar age and sex distributions: 24 nondiabetic patients with angiographically verified coronary atherosclerosis, i.e., coronary heart disease (CHD); 11 nondiabetic patients with angiographically verified peripheral atherosclerosis, i.e., peripheral arterial disease (PAD); 42 clinically healthy subjects recruited from the Copenhagen City Heart Study, a major epidemiological general population study of cardiovascular disease and risk factors [8, 9] ; and 60 patients with diabetes mellitus (27 with type 1 diabetes and 33 with type 2 diabetes). Among the diabetes patients, 21 (35%) had clinical symptoms of CHD or PAD, but the diagnosis was only verified by angiography in 5 (8%). Insulin was instituted in 48 (80%) of the diabetes patients, whereas the rest were on oral antidiabetic agents; 7 (12%) received beta adrenoceptor blockers; 11 (18%) calcium channel blockers; 16 (27%) angiotensin-converting enzyme inhibitors or angiotensin II-receptor blockers; and 8 (13%) statins. In patients with CHD, 10 (42%) received beta adrenoceptor blockers; 7 (29%) calcium channel blockers; 18 (75%) angiotensin-converting enzyme inhibitors or angiotensin IIreceptor blockers; and 18 (75%) statins. In patients with PAD, 2 (18%) received calcium channel blockers and 2 (18%) angiotensin-converting enzyme inhibitors or angiotensin II-receptor blockers; whereas none were on beta adrenoceptor blockers or statins. All participants gave written informed consent. The study was in accordance with the Declaration of Helsinki and was approved by the Copenhagen and Frederiksberg Ethics Committee (file no. 01-302/97). The study was surveyed by the Danish National Department of Isotope Pharmacy who permitted investigation of maximally two subjects per week.
Procedures
Fractional escape rates of low-density lipoprotein (FER LDL ) and albumin (FER alb ) were measured by means of plasma decay curves 1 h after intravenous injection of autologous 131-iodinated LDL ( 131 I-LDL) and commercially available 125-iodinated human serum albumin ( 125 Ialbumin), respectively. LDL was isolated from 100 ml of blood by sequential ultracentrifugation at 4 8C in solvent densities of 1.019 and 1.050 g/ml, respectively, at 50,000 rpm for 20 h in a Beckman 50.4 Ti rotor. 131-Iodination of LDL was done with 18.5 MBq 131-iodine using iodine monochloride [10] . The iodination efficiency was 25F5% (n=54) which corresponds to 52F13 cpm/ng LDL protein. In the labeled preparations, 98.6F0.4% of the 131 I radioactivity was precipitable with 15 vol./vol.% trichloroacetic acid (TCA), and 5.6F0.5% of the 131 I radioactivity was lipid-soluble, i.e., extractable into chloroform-methanol (1:1, vol/vol). In fixed-density ultracentrifugation analysis of labeled LDL in the presence of added carrier plasma, z96% of the total radioactivity was in the LDL density range of 1.019-1.063 g/ml. No evidence of fragmentation of the labeled LDL was detected using a 3% to 8% Tris-Acetate Gradient Gel followed by autoradiography. In all labeled preparations, test for sterility was negative, and b5 pg of pyrogenes was detectable per milliliter sample.
The participants met at 0800 h after an 8-h fast and tobacco abstinence. A 17-G Teflon cannula was inserted in an antecubital vein in both arms, one for blood sampling and one for injection. After 30-min rest at recumbency, the preparation containing 131 I-LDL (700 kBq) and 125 Ialbumin [500 kBq; code IFE-IT.23S or IFE-IT.20S, Isopharma, Kjeller, Norway (free 125 I radioactivity b1.5F 0.2%)] was injected intravenously. Venous blood samples of 10 ml were drawn without stasis in heparinized tubes before and at 10, 20, 30, 40, 50 , and 60 min after injection. Proteins in plasma (3 ml) and doses (0.1 ml with 2.9 ml unlabeled plasma added) were precipitated at 4 8C with TCA at a final concentration of 15 vol.%/vol.%. Following mixing and centrifugation, total radioactivity as well as radioactivity in the supernatant was counted for 20 min in a double-channel gamma counter (1282 Compugamma, LKB, Wallac, Turku, Finland). For both tracers, the TCA-precipitable radioactivity at each time point was plotted versus time after logarithmic transformation. FER LDL and FER alb (in %/h) were then calculated on the basis of the slopes (b) of the best linear curves fitted by the least squares method using the formula (1À60e b )Â100%, thus assuming that radioactivities declined monoexponentially with time (1-compartment system). Distribution volumes of LDL (DV LDL ) and albumin (DV alb =plasma volume) were calculated from the amounts of injected radioactivities divided by the plasma radioactivities at time zero, as derived from the intercepts of the fitted lines for the two tracers, respectively. The obtained DV values were corrected for body surface area (m 2 ) by the formula 0.007184Âweight 0.425 Â height 0.725 . Because there could be an inflection point of the decay curves after only 30 min, curve fits of both 60 and 30 min after reinjection were used for calculations. Finally, the absolute net efflux of LDL cholesterol, J LDL in mmol/ (m 2 Âh) was calculated by the formula FER LDL ÂDV LDL Â plasma LDL cholesterol.
The contribution of receptor mediated elimination of LDL from the intravascular compartment to FER LDL during the 1-h blood sampling period was elucidated by comparing FER LDL with FER Gly-LDL in three humans without diabetes mellitus [3] . Glycosylated LDL is not recognized by LDL receptors [11, 12] , and thus the difference between FER LDL and FER Gly-LDL represents receptor elimination. Glycosylation of LDL was performed as previously described by others [11, 13, 14] . Autologous 131 I-LDL (700 kBq) and autologous 125 I-Gly-LDL (500 kBq) was reinjected under similar conditions as described above. Venous blood samples of 10 ml were drawn without stasis in heparinized tubes before and at 10, 20, 30, 40, 50, and 60 min after reinjection. Eleven additional blood samples were obtained during the subsequent 6 days. Plasma was precipitated with TCA and counted for radioactivity as described above. For both tracers, the logarithmically transformed TCA-precipitable radioactivity was plotted versus time, and FER LDL and FER Gly-LDL were calculated as previously described. Mean FER LDL was about 1%/h higher than mean FER Gly-LDL (3.6F1.1%/h vs. 2.6F1.1%/h). Moreover, fractional catabolic rates, FCR LDL and FCR Gly-LDL (in %/h), were calculated according to Matthews [15] using the formula
À1 , where b 1 and b 2 are slopes and C 1 and C 2 intercepts of the late and initial linear curve fits, respectively. Mean FCR LDL was about two times higher than mean FCR Gly-LDL ( Pb0.01), documenting that Gly-LDL was indeed glycosylated.
The use of a 1-compartment system for calculation of FER LDL was validated by comparing FER LDL with transvascular LDL permeability as described by Matthews [15] , which takes into account an extravascular protein compartment, receptor-mediated metabolism, and excretion. In eight subjects without diabetes, blood samples were collected every 10 min during the first hour and subsequently once a day during the next week upon reinjection of autologous 131 I-LDL. Transvascular LDL permeability using the multicompartment model was calculated by the formula [15] . There was a positive correlation between FER LDL using 1-compartment kinetics and transvascular LDL permeability using multicompartment kinetics (R 2 =0.41; n=8; one-sided Pb0.05). The equation for the linear correlation was 1-compartment FER LDL =0.43Âmulticom-partment FER LDL +2.8 (all in %/h). The overestimation of FER LDL by 1-compartment kinetics was most pronounced in the lower range.
Finally, we correlated FER LDL to FCR LDL in 27 subjects, where FCR LDL was calculated by multicompartmental analysis using the SAAM II software (SAAM Institute, Seattle, WA) [16] . Because there was no correlation between FER LDL and FCR LDL (Rb0.01; n=27; P=0.99), it is unlikely that metabolism, i.e., receptor-mediated elimination of LDL, contributes to FER LDL to any significant degree.
Plasma concentrations of total cholesterol, LDL cholesterol, high-density lipoprotein (HDL) cholesterol, and triglycerides, and blood concentration of glucose were all measured by commercially available assays (Roche Diagnostics, Mannheim, Germany) using a Hitachi analyzer. Plasma concentration of insulin was measured by a fluoroimmunoassay. Fraction of glycosylated hemoglobin in blood, hemoglobinA 1c , was measured by high-performance liquid chromatography. LDL particle diameter was measured by nondenaturing pore gradient gel electrophoresis as previously described [3, 17] . All blood samples were drawn after an 8-h fast and tobacco abstinence. Systolic and diastolic blood pressures were measured by auscultation using a manometre and an appropriately sized cuff. Body mass index (BMI; kg/m 2 ) was calculated as weight/height 2 .
Statistical analysis
Comparisons between groups were performed by Student's t-test, analysis of variance (ANOVA), or the v 2 test. Factors associated with FER LDL were analyzed by linear regression analyses. Plasma triglycerides, plasma insulin, and blood hemoglobinA 1c were log-transformed prior to the analyses because of nonnormal distribution. P-valuesb0.05 were significant. We used the SPSS version 11.0 statistical software package.
Results
Characteristics of the four study groups are given in Table  1 . Patients with peripheral arterial disease (PAD) had higher systolic blood pressure, plasma triglycerides, plasma Creactive protein, and proportion of smokers than controls. Patients with coronary heart disease (CHD) had higher body mass index, plasma triglycerides, plasma insulin, and plasma C-reactive protein and lower plasma LDL cholesterol and HDL cholesterol than healthy controls. Diabetes patients had higher systolic blood pressure, body mass index, plasma insulin, hemoglobinA 1c , and plasma C-reactive protein and lower plasma LDL cholesterol, LDL diameter and plasma triglycerides than controls (Tables 1 and 2 ).
The mean plasma decay curves for 131 I-LDL in patients with CHD+PAD, diabetes, and healthy controls are given in Fig. 1 : evaluation of these raw data suggests that iodinated LDL disappears faster from plasma in diabetes patients versus controls, but not in patients with CHD+PAD versus controls.
Patients with CHD or PAD had similar FER LDL as healthy controls, irrespective of adjustment for differences in DV LDL (Table 2 ) or other covariates as listed above (data not shown). To increase the statistical power for comparison with controls, CHD and PAD patients were combined because both groups are thought to have universal atherosclerosis: FER LDL in CHD+PAD patients did not differ from that in controls, unadjusted or adjusted for DV LDL (Fig. 2) .
Diabetes patients had significantly higher FER LDL than controls (Table 2 and Fig. 2 ). Due to variations in DV LDL between groups, this difference was even more pronounced after correction for DV LDL (Table 2 and Fig. 2), and it remained statistical significance after adjustment for systolic blood pressure, body mass index, plasma insulin, hemoglobinA 1c , C-reactive protein, plasma LDL cholesterol, LDL diameter, and plasma triglycerides (data Table 2 Fractional escape rates (FER), distribution volumes (DV), and absolute net efflux (J) of LDL and albumin, and LDL size in patients with diabetes mellitus, coronary heart disease (CHD), peripheral arterial disease (PAD), and healthy controls After correction for DV alb , FER alb was also elevated in diabetes patients compared with controls (Table 2 and Fig.  3 ). This was also the case in patients with PAD, whereas patients with CHD had FER alb similar to healthy controls (Table 2) . However, CHD+PAD patients had FER alb similar to that of controls (Fig. 3) .
FER LDL and FER alb were generally higher when only the initial 30 min of the decay curves were used, which is in support of a possible inflection point at about 30 min after reinjection. However, the relative differences between groups were of similar magnitude as the corresponding 60-min values ( Table 2 ). Net efflux of LDL cholesterol form the plasma compartment, J LDL , was due to a lower DV LDL not elevated in diabetes patients versus controls, but significantly reduced in patients with PAD ( Table 2) .
There was a tight positive correlation between FER LDL and FER alb in patients with CHD+PAD, diabetes patients, as well as in healthy controls (Fig. 4) . This was true for unadjusted values, values adjusted for differences in distribution volumes of LDL and albumin, respectively, as well as values adjusted for other covariates as listed above (latter not shown).
Apart from blood glucose lowering agents, lesser medication was instituted in diabetes patients than in Fig. 2 . Distributions of FER LDL in patients with coronary heart disease (CHD) or peripheral artery disease (PAD) (n=35), diabetes (n=60), and in healthy controls (n=42). Left panels show unadjusted values and right panels show values adjusted for variation in distribution volume of LDL, respectively. Mean values are given for each group, and two-sided t-tests were used for comparison between patient groups and controls (only 60-min values are shown). patients with CHD or PAD. The use of insulin or oral antidiabetic agents was not associated with FER.
Discussion
The present study has shown that patients with presence of clinical atherosclerosis in either coronary or lower extremity arteries have transendothelial exchange of lowdensity lipoprotein (measured as FER LDL ) similar to that of healthy controls, while patients with diabetes mellitus have higher FER LDL values than controls. It is therefore not likely that increased transendothelial LDL exchange in diabetes is due to atherosclerosis per se but rather is due to some other factors in the diabetes state. This could be generalized vascular leakiness of macromolecules, i.e., increased permeability, which is not seen in nondiabetic subjects. Our observations are particularly important because they, for the first time, support that vascular LDL leakiness could precede development of atherosclerosis in diabetes and therefore may help explain the accelerated atherosclerosis seen in diabetes. The reason why FER LDL is not increased in nondiabetic patients with atherosclerosis could be that such patients have only localized arterial lesions in contrast to diabetes patients who may have microvascular as well as macrovascular leakiness.
It is well recognized that diabetes patients have more atherosclerosis than controls [18] . Generally, patients with type 1 diabetes are at an increased coronary heart disease risk only if they have renal disease [19] , although FER LDL was not correlated to diabetes duration, microalbuminuria, or renal disease [4] . This is different from type 2 diabetes where insulin resistance predominates and the risk of atherosclerosis starts very early [20] . Because atherosclerotic lesions per se increase arterial LDL influx to intima [7] , it is important to exclude that the larger FER LDL in diabetes patients versus controls [3, 4] is not simply caused by atherosclerosis, rather than the opposite. As patients with PAD or CHD likely have more atherosclerosis than diabetes patients in the present study, our demonstration of elevated FER LDL in diabetics, but not in those with PAD or CHD who have severe atherosclerosis, excludes that increased transendothelial LDL exchange in diabetes is caused by severe atherosclerosis. Therefore, vascular LDL leakiness in diabetes likely may lead to accelerated atherogenesis, as increased arterial permeability to LDL is associated with later increased development of atherosclerosis after exposure to hyperlipidemia [21] . An alternative explanation of elevated FER LDL in diabetes patients may be that FER LDL reflects metabolism of LDL rather than transendothelial exchange. However, at least four points are against this possibility:
(1) The difference in FER LDL between diabetes patients and controls remained unaffected after adjustment for plasma LDL levels. If metabolism was operating, the number of hepatic LDL receptors and consequently uptake of labeled LDL would depend on the concentration of unlabeled LDL in plasma [22] ; (2) the distribution volume of LDL was smaller in diabetes patients than in controls, excluding that uptake of LDL by LDL receptors should be larger in diabetes patients versus controls; (3) not only FER LDL but also FER alb was elevated in diabetes patients, and FER alb cannot be influenced by LDL metabolism; and (4) there was no relationship between FER LDL and FCR LDL .
Glycosylation of LDL in patients with diabetes could also influence LDL receptor elimination in diabetes patients versus controls. Thus, glycosylated LDL is not recognized by LDL receptors [11, 12] , as confirmed by the significantly lower FCR Gly-LDL than FCR LDL in our validation experiments. We therefore studied the contribution of receptor elimination to FER LDL by measuring FER Gly-LDL and FER LDL simultaneously. FER Gly-LDL was about 1%/h lower than FER LDL in nondiabetic humans, indicating that receptor elimination contributes to FER LDL only by approximately 1%/h (corresponding to about one-third of FER LDL ). This is in accordance with the overestimation of FER LDL by 1-3%/h when our 1-compartment model is used compared with a multicompartment model which subtracts the contribution of metabolism [15] . It is also in accordance with the slightly bigger distribution volume of LDL than albumin. Importantly, because glycosylation of LDL particles may be increased-although far below 100%-in diabetes patients due to the hyperglycemic milieu, LDL glycosylation does not explain the difference in FER LDL between diabetic patients and healthy subjects observed in this study, but rather the difference may be underestimated.
Yet another possibility is that the smaller LDL diameter in diabetes patients may explain the difference in FER LDL between diabetic patients and controls. Small LDL enters faster into the vessel wall than large LDL [10] , and small LDL is associated with increased risk of coronary heart disease [23] . However, some arguments do not support this possibility:
(1) LDL diameter was not (inversely) correlated with FER LDL ; (2) not only FER LDL but also FER alb was elevated in diabetes patients versus controls, and FER alb cannot be influenced by LDL diameter; and (3) the difference in FER LDL between diabetes patients and controls remained unaffected after adjustment for LDL diameter.
Because FER LDL was also independent of systemic arterial blood pressure and endothelial surface area as reflected by the plasma volume, we suggest the elevated FER LDL in diabetes patients to result mainly from increased transvascular permeability. This could be a consequence of endothelial cell death or damage [24] [25] [26] due to, e.g., hyperinsulinemia [27] [28] [29] , or to circulating advanced glycation end products (AGE) inducing transvascular hyperpermeability [30] [31] [32] [33] . However, other authors have observed increased intimal LDL accumulation before the formation of AGE and suggest a direct effect of hyperglycemia on the vessel wall [34] .
The main proportion of transendothelial LDL exchange probably takes place in the capillaries. However, there exists indirect evidence for similar exchange of albumin and lipoproteins in capillaries and arteries [35] . Furthermore, the tight positive correlation between FER LDL and FER alb observed in this study is analogous with the correlation between the transport of LDL and albumin across the arterial wall in rabbits [36] . The significantly lower FER LDL than FER alb is in accordance with the three-times-larger diameter of LDL particles than of albumin.
In conclusion, this human in vivo study has shown that transendothelial exchange of LDL particles from the intravascular compartment is unaffected by presence of severe atherosclerosis. In contrast, among patients with diabetes mellitus, this exchange was elevated. We believe that this difference is likely due to increased vascular leakiness of LDL in diabetes patients, potentially leading to increased LDL accumulation in the vessel wall and thus progressed atherosclerosis. Our study could not identify this mechanism in nondiabetic individuals with symptomatic and angiographically verified atherosclerosis, suggesting that this phenomenon is unique for diabetes patients.
